Systemic Therapy for Unresectable Metastatic Melanoma: Impact of Biochemotherapy on Long-Term Survival

REFERENCES

• Ahmann D. L., Creagan E. T., Hahn R. G., Edmonson J. H., Bisel H. F., Schaid D. J. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 1989; 63: 224–227
   PubMed Web of Science ®Google Scholar
• Allen I. E., Kupelnick B., Kumashiro M., Luo D., Ross S. D., Wolin M. J. Efficacy of interleukin-2 in the treatment of metastatic melanoma: Systematic review and meta-analysis. Cancer Ther. 1998; 1: 168–173
   Google Scholar
• Anderson C. M., Buzaid A. C., Legha S. S. Systemic treatments for advanced cutaneous melanoma. Oncology 1995; 9: 1149–1168
   PubMedGoogle Scholar
• Atkins M. B., Lee S., Flaherty L. E., Sosman J. A., Sondak V. K., Kirkwood J. M., for the U.S. Melanoma Intergroup. A prospective randomized Phase III trial of concurrent Biochemotherapy (BCT) with cisplatin, Vinblastine, DTIC (CVD), IL-2 and interferon α 2b (IFN) versus CVD alone in patients with metastatic melanoma (E3695): An ECOG-coordinated intergroup trial. Proc. ASCO 2003; 22, (Abstract #2847)
   Google Scholar
• Atkins M. B., Lotze M. T., Dutcher J. P., Fisher R. I., Weiss G., Margolin K., Abrams J., Sznol M., Parkinson D., Hawkins M., Paradise C., Kunkel L., Rosenberg S. A. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999; 17: 2105–2116
   PubMed Web of Science ®Google Scholar
• Atkins M. B., O'Boyle K. R., Sosman J. A., Weiss G. R., Margolin K. A., Ernest M. L., Kappler K., Mier J. W., Sparano J. A., Fisher R. I., Eckardt J. R., Pereira C., Aronson F. R. Multi-institutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol. 1994; 12: 1553–1560
   PubMed Web of Science ®Google Scholar
• Atzpodien J., Neuber K., Kamanabrou D., Fluck M., Bröcker E. B., Neumann C., Rünger T. M., Schuler G., von den Driesch P., Müller I., Paul E., Patzelt T., Reitz M. Combination chemotherapy with or without subcutaneous IL-2 and 1FNα : Results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br. J. Cancer 2002; 86: 179–184
   PubMed Web of Science ®Google Scholar
• Buzaid A. C., Legha S., Winn R., Belt R., Pollock T., Wiseman C., Ensign L. G. Cisplatin (C), vinblastine (V), DTIC (D) (CVD) versus DTIC alone in metastatic melanoma: Preliminary results Phase III cancer community oncology program (CCOP). Proc. Am. Soc. Clin. Oncol. 1993; 12: 1328, (Abstract #1328)
   Google Scholar
• Chapman P. B., Einhorn L. H., Meyers M. L., Saxman S., Destro A. N., Panageas K. S., Begg C. B., Agarwala S. S., Schuchter L. M., Ernstoff M. S., Houghton A. N., Kirkwood J. M. Phase III multi-center randomized trial of the Dartmouth regimen versus DTIC in patients with metastatic melanoma. J. Clin. Oncol. 1999; 17: 2745–2751
   PubMed Web of Science ®Google Scholar
• Cox D. R. Regression models and lifetables. J. Royal Stat. Soc. B 1972; 34: 187–202
   Web of Science ®Google Scholar
• Del Prete S. A., Maurer L. H., O'Donnell J., Forcier R. J., LeMarbre P. Combination chemotherapy with cisplatin, carmustine, DTIC, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 1984; 68: 1403–1405
   PubMedGoogle Scholar
• Dudley M. E., Wunderlich J. R., Robbins P. F., Yang J. C., Hwu P., Schwartzentruber D. J., Topalian S. L., Sherry R., Restifo N. P., Hubicki A. M., Robinson M. R., Raffeld M., Duray P., Seipp C. A., Rogers-Freezer L., Morton K. E., Mavroukakis S. A., White D. E., Rosenberg S. A. Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes. Science 2002; 298: 850–854
   PubMed Web of Science ®Google Scholar
• Eton O., Legha S. S., Bedikian A. Y., Lee J. J., Buzaid A. C., Hodges C., Ring S. E., Papadopoulos N. E., Plager C., East M. J., Zhan F., Benjamin R. S. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a Phase III randomized trial. J. Clin. Oncol. 2002; 20: 2045–2052
   PubMed Web of Science ®Google Scholar
• Flaherty L. E., Atkins M., Sosman J., Weiss G., Clark J. I., Margolin K., Dutcher J., Gordon M. S., Lotze M., Mier J., Sorokin P., Fisher R. I., Appel C., Du W. Outpatient Biochemotherapy with interleukin-2 and interferon-α 2b in patients with metastatic malignant melanoma: Results of two Phase II cytokine working group trials. J. Clin. Oncol. 2001; 19: 3194–3202
   PubMed Web of Science ®Google Scholar
• Hauschild A., Garbe C., Stolz W., Ellwanger U., Seiter S., Dummer R., Ugurel S., Sebastian G., Nashan D., Linse R., Achtelik W, Mohr P., Kaufmann R., Fey M., Ulrich J., Tilgen W. Dacarbazine and interferon-α with or without interleukin 2 in metastatic melanoma: A randomized Phase III multicenter trial of the Dermatologic Oncology Group (DeCOG). Br. J. Cancer 2001; 84: 1036–1042
   PubMed Web of Science ®Google Scholar
• Johnston S. R., Constenia D. O., Moore J., Atkinson H., A'Hern R. P., Dadian G., Riches P. G., Gore M. E. Randomized Phase II trial of BCDT [carmustine (BCNU), cisplatin, DTIC (DTIC), and Tamoxifen] with or without interferon-alpha (IFN〈) and interleukin-2 (IL-2) in patients with metastatic melanoma. Br. J. Cancer 1998; 77: 1280–1286
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
   Web of Science ®Google Scholar
• Keilholz U., Punt C. J., Gore M., Kruit W., Patel P., Lienard D., Thomas J., Proebstle T. M., Schmittel A., Schadendorf D., Velu T., Negrier S., Kleeberg U., Lehman F., Suciu S., Eggermont A. M. DTIC, cisplatin and interferon-〈 2b with or without interleukin-2 in metastatic melanoma: A randomized Phase III trial (18951) of the European Organization for Research and Treatment of Cancer Melanoma. J. Clin. Oncol. 2005; 23: 6747–6755
   PubMed Web of Science ®Google Scholar
• Khayat D., Borel C., Tourani J. M., Benhammouda A., Antoine E., Rixe O., Vuillemin E., Bazex P. A., Thill L., Franks R., Auclerc G., Soubrane C., Banzet P., Well M. Sequential chemoimmunotherapy with cisplatin, interleukin-2 and interferon-〈 2a for metastatic melanoma. J. Clin. Oncol. 1993; 11: 2173–2180
   PubMed Web of Science ®Google Scholar
• Kim B., Eton O., East M. J., Hodges C., Plager C., Papadopoulos N. E., Rohl C., Grimm E. A., Bedikian A. Y. Pilot study of high dose concurrent biochemotherapy for advanced melanoma. Cancer 2004; 101: 596–603
   PubMed Web of Science ®Google Scholar
• Legha S., Ring S., Bedikian A. Y., Eton O., Plager C., Papadopoulos N. E., Ensign L. G., Benjamin R. S. Lack of benefit from tamoxifen (T) added to a regimen of cisplatin (C), vinblastine (V), DTIC (D) and α -interferon (IFN) in patients (pts) with metastatic melanoma (MM). Proc. Am. Soc. Clin. Oncol. 1993; 12: 388
   Google Scholar
• Legha S. S., Ring S., Bedikian A. Y., Plager C., Eton O., Buzaid A. C., Papadopoulos N. E. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and DTIC (CVD) and biotherapy using interleukin-2 and interferon-α. Ann. Oncol. 1996; 7: 827–835
   PubMed Web of Science ®Google Scholar
• Legha S. S., Ring S., Eton O., Bedikian A., Buzaid A. C., Plager C., Papadopoulos N. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, DTIC, interferon-α, and interleukin-2 for patients with metastatic melanoma. J. Clin. Oncol. 1998; 16: 1752–1759
   PubMed Web of Science ®Google Scholar
• Legha S. S., Ring S., Eton O., Bedikian A., Plager C., Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center Experience. Cancer J. Sci. Am. 1997; 3: S9–S15
   PubMed Web of Science ®Google Scholar
• Legha S. S., Ring S., Papadopoulos N., Plager C., Chawla S., Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and DTIC (CVD) for metastatic melanoma. Cancer 1989; 64: 2024–2029
   PubMed Web of Science ®Google Scholar
• Lotze M. T., Dallal R. M., Kirkwood J. M., Flickinger J. C. Cutaneous melanoma. Cancer: Principles & Practice of Oncology, 6th Edition, V. T. DeVita, Jr, S. Hellman, S. A. Rosenberg. Lippincott, Williams & Wilkins, Philadelphia 2001; 2:2012–2069
   Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966; 50: 163–170
   PubMedGoogle Scholar
• Middleton M. R., Grob J. J., Aaronson N., Fierlbeck G., Tilgen W., Seiter S., Gore M., Aamdal S., Cebon J., Coates A., Dreno B., Henz M., Schadendorf D., Kapp A., Weiss J., Fraass U., Statkevich P., Muller M., Thatcher N. Randomized Phase III study of temozolomide vs. DTIC in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol. 2000; 18: 158–166
   PubMed Web of Science ®Google Scholar
• Millard M. J., Bedikian A. Y, Conry R. M., Gore M. E., Pehamberger H. E., Sterry W., Pavlick A. C., De Conti R. C., Gordon D., Itri L. M. Randomized multinational Phase 3 trial of DTIC (DTIC) with or without Bcl-2Antisense (oblimersen sodium) in patients (pts) with advanced malignant melanoma (MM): Analysis of long-term survival. Proc. Am. Soc. Clin. Oncol. 2004; 23: 708, (#7505)
   Google Scholar
• O'Day S. J., Gammon G., Boasberg P. D., Martin M. A., Kristedja T. S., Guo M., Stern S., Edwards S., Fournier P., Weisberg M., Cannon M., Fawzy N. W., Johnson T. D., Essner R., Foshag L. J., Morton D. L. Advantages of concurrent Biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma. J. Clin. Oncol. 1999; 17: 2752–2761
   PubMed Web of Science ®Google Scholar
• Papadopoulos N., Bedikian A. Y., Ring S., Kim K. B., Camacho L. H., Eton O. Phase II study of CTD (cisplatin, paclitaxel, DTIC) in metastatic melanoma (MM). Proc. Am. Soc. Clin. Oncol. 2003; 22, (Abstract #2889)
   Google Scholar
• Richards J. M., Mehta N., Ramming K., Skosey P. Sequential chemoimmunotherapy in treatment of metastatic melanoma. J. Clin. Oncol. 1992; 10: 1338–1343
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Seipp C. A., Einhorn J. H., White D. E., Steinberg S. M. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, DTIC, and tamoxifen alone or in combination with interleukin-2 and interferon α 2b. J. Clin. Oncol. 1999; 17: 968–975
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994; 271: 907–913
   PubMed Web of Science ®Google Scholar
• Thompson J. A., Gold P. J., Fefer A. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Sem. Oncol. 1997; 24(S14)S44–S48
   PubMedGoogle Scholar
• WHO. World Health Organization. Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva 1979
   Google Scholar
• Yee C., Thompson J. A., Byrd D., Riddell S. R., Roche P., Celis E., Greenberg P. D. Adoptive T-cell therapy using antigen-specific CD8+ T-cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and anti-tumor effect of transferred T-cells. Proc. Natl. Acad. Sci. USA 2002; 99: 16168–16173
   PubMed Web of Science ®Google Scholar
• Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nature Med. 2008; 8: 59–73
   Google Scholar